CS231295, a selective inhibitor of brain-penetrating Aurora B, is exclusively discovered by the company with global patent protection. Aurora B is specifically overexpressed in a variety of tumors and is associated with tumor prognosis. Therefore, Aurora B inhibition may result in targeted tumor killing. For tumors with RB1 deletion and other potential gene deletions, CS231295 produces a synthetic lethal effect and provides targeted efficacy. Meanwhile, CS231295 has a significant tumor angiogenesis inhibition effect and achieves broad-spectrum anti-tumor activity. In addition, CS231295 has good blood-brain barrier permeability, has obvious therapeutic advantages for primary and metastatic brain tumors, and has good application potential in the treatment of malignant brain tumors and brain metastases. With its unique mechanism and chemical structure, CS231295 has synergistic therapeutic effects with chemotherapy, targeted therapy, and immunotherapy. Significant pharmacodynamic activity, desirable pharmacokinetic characteristics, and good safety of CS231295 have been demonstrated in preclinical studies.

Indications under development

• In Dec. 2024, the investigational new drug (IND) application for CS231295 tablets was approved by the NMPA, and a phase 1 clinical trial is currently in preparation.
• The company will perform the overseas investigational of new drug (IND) applications for monotherapy and combination therapies of this molecule in due course.